Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Inclusion Criteria:

• Participants legally competent to sign and give informed consent or informed consentof legal guardian, and, if age appropriate, assent by the subject, as required bylocal laws

• Males and females ages 2 years and older (inclusive)

• Subjects with chronic plaque psoriasis who meet eligibility criteria and:

1. Successfully completed a prior ARQ-151 cream study in psoriasis (Cohort 1) or

2. Are naïve to treatment with ARQ-151 cream (Cohort 2)

• Females of childbearing potential (FOCBP) must have a negative pregnancy test at allstudy visits. In addition, sexually active FOCBP must agree to use at least one formof highly effective contraception throughout the trial.

Exclusion Criteria:

• Subjects who experienced an ARQ-151 treatment-related AE or a serious AE (SAE) thatprecluded further treatment with ARQ-151 cream in a prior ARQ-151 cream study.

• Planned excessive exposure of treated area(s) to either natural or artificialsunlight, tanning bed or other LED.

• Females who are pregnant, wishing to become pregnant during the study, or arebreast-feeding.

• Subjects with any serious medical condition or laboratory abnormality that wouldprevent study participation or place the subject at significant risk, as determinedby the Investigator.

• Subjects with a history of chronic alcohol or drug abuse within 6 months ofinitiation of investigational product.

• Subjects who are unable to communicate, read or understand the local language, orwho display another condition, which in the Investigator's opinion, makes themunsuitable for clinical study participation.